Which visual‑field test that begins with “G” is used to assess pituitary macroadenoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Goldmann Perimetry for Pituitary Macroadenoma Assessment

Goldmann perimetry is the visual field test beginning with "G" that is preferred for assessing pituitary macroadenomas. 1

Why Goldmann Perimetry is Preferred

Goldmann perimetry is explicitly recommended as the preferred method for visual field testing in patients with pituitary macroadenoma. 1 This kinetic perimetry technique allows comprehensive mapping of the entire visual field and is particularly effective at detecting the characteristic bitemporal hemianopsia caused by optic chiasm compression. 1

Alternative Testing Options

  • Automated static perimetry (such as Humphrey visual field testing) serves as an acceptable alternative when Goldmann perimetry is unavailable. 1
  • Automated perimetry reliably detects subtle bitemporal field defects, occasional homonymous defects, and arcuate defects characteristic of optic nerve pathology that patients may not subjectively notice. 1

Complete Visual Assessment Protocol

Beyond visual field testing, comprehensive ophthalmologic evaluation must include:

  • Visual acuity measurement using age-appropriate logarithm of the minimum angle of resolution (logMAR) charts to provide quantitative baseline data. 2, 1
  • Fundoscopy to evaluate optic disc appearance and optic nerve integrity, which provides prognostic information on visual recovery potential. 1
  • Baseline optical coherence tomography (OCT) in patients with potentially severe acuity or field deficits, as retinal nerve fiber layer (RNFL) thickness serves as a surrogate marker for visual field loss. 1

Timing Considerations

  • Pre-treatment assessment is mandatory for all patients with suspected or confirmed pituitary macroadenoma to identify asymptomatic visual deficits and establish baseline for comparison. 1
  • Post-treatment follow-up should occur within 3 months of first-line therapy, as further recovery of visual field deficits is unlikely after the first postoperative month. 2, 1

Clinical Pitfalls

Visual field defects can occur even without suprasellar extension on imaging, while some patients with suprasellar masses elevating the chiasm may paradoxically have normal visual fields. 3 Therefore, never rely on imaging alone to predict visual involvement—always perform formal visual field testing regardless of tumor appearance on MRI. 3

References

Guideline

Guideline for Ophthalmologic Evaluation in Pituitary Macroadenoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Visual field defects in 23 acromegalic patients.

International ophthalmology, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.